Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity

Marylyn D. Ritchie; David W. Haas; Alison A. Motsinger; John P. Donahue; Huso Erdem; Stephen Raffanti; Peter Rebeiro; Alfred L. George; Richard B. Kim; Jonathan L. Haines; Timothy R. Sterling

doi:10.1086/507101

Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity

Marylyn D. Ritchie
, David W. Haas
, Alison A. Motsinger
, John P. Donahue
, Huso Erdem
, Stephen Raffanti
, Peter Rebeiro
, Alfred L. George
, Richard B. Kim
, Jonathan L. Haines
, Timothy R. Sterling

Biochemistry & Molecular Biology

Research output: Contribution to journal › Article › peer-review

100 Scopus citations

Abstract

This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenzor nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C→T (odds ratio, 0.254; P = .021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P < .001).

Original language	English (US)
Pages (from-to)	779-782
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	43
Issue number	6
DOIs	https://doi.org/10.1086/507101
State	Published - Sep 15 2006

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Infectious Diseases

Access to Document

10.1086/507101

Cite this

@article{529db163779049b68d7f2cb5fbce4e3a,

title = "Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity",

abstract = "This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenzor nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C→T (odds ratio, 0.254; P = .021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82\% accuracy (P < .001).",

author = "Ritchie, \{Marylyn D.\} and Haas, \{David W.\} and Motsinger, \{Alison A.\} and Donahue, \{John P.\} and Huso Erdem and Stephen Raffanti and Peter Rebeiro and George, \{Alfred L.\} and Kim, \{Richard B.\} and Haines, \{Jonathan L.\} and Sterling, \{Timothy R.\}",

note = "Funding Information: Financial support. The Vanderbilt Meharry Center for AIDS Research (funded by the National Institute of Allergy and Infectious Diseases [NIAID; grant P30 AI 54999]) and the NIAID (grant K23 AI01654 [to T.R.S.], grant HL65962 [to M.D.R.], and grant RR000095 to the Vanderbilt General Clinical Research Center).",

year = "2006",

month = sep,

day = "15",

doi = "10.1086/507101",

language = "English (US)",

volume = "43",

pages = "779--782",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity

AU - Ritchie, Marylyn D.

AU - Haas, David W.

AU - Motsinger, Alison A.

AU - Donahue, John P.

AU - Erdem, Huso

AU - Raffanti, Stephen

AU - Rebeiro, Peter

AU - George, Alfred L.

AU - Kim, Richard B.

AU - Haines, Jonathan L.

AU - Sterling, Timothy R.

N1 - Funding Information: Financial support. The Vanderbilt Meharry Center for AIDS Research (funded by the National Institute of Allergy and Infectious Diseases [NIAID; grant P30 AI 54999]) and the NIAID (grant K23 AI01654 [to T.R.S.], grant HL65962 [to M.D.R.], and grant RR000095 to the Vanderbilt General Clinical Research Center).

PY - 2006/9/15

Y1 - 2006/9/15

N2 - This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenzor nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C→T (odds ratio, 0.254; P = .021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P < .001).

AB - This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenzor nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C→T (odds ratio, 0.254; P = .021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P < .001).

UR - https://www.scopus.com/pages/publications/33748288115

UR - https://www.scopus.com/pages/publications/33748288115#tab=citedBy

U2 - 10.1086/507101

DO - 10.1086/507101

M3 - Article

C2 - 16912956

AN - SCOPUS:33748288115

SN - 1058-4838

VL - 43

SP - 779

EP - 782

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 6

ER -

Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this